Trials / Completed
CompletedNCT00996125
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 9 Years – 17 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years. One group of subjects will receive the HPV vaccine and the other group will receive the control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CervarixTM | Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule. |
| OTHER | Control | Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule. |
Timeline
- Start date
- 2009-10-24
- Primary completion
- 2010-12-08
- Completion
- 2010-12-08
- First posted
- 2009-10-16
- Last updated
- 2018-08-17
- Results posted
- 2012-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00996125. Inclusion in this directory is not an endorsement.